Retigabine alleviates cognitive deficits, decreases neuropathology and activates the AKT/GSK-3β pathway in APP/PS1 transgenic mice
Behavioural Brain Research · 2026-10 · 514 · 116391
DOI: 10.1016/j.bbr.2026.116391 ↗Kurz gefasst
Fachartikel in der Zeitschrift Behavioural Brain Research, 2026-10. Verfasst von Xinyao Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Qingdao University Medical College, China. Electronic address: zhangxinyao0810@163.com. Hauptthemen laut MEDLINE: Phenylenediamines, Alzheimer Disease, Carbamates, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, Shandong Province Natural Science Foundation, Department of Science and Technology of Guangdong Province.
Abstract (Originalsprache)
Neuronal hyperexcitability is crucial to the pathogenesis of Alzheimer's disease (AD). Activating the Kv7 channel is an effective way to reduce neuronal excitability. The Kv7 channel opener retigabine (RTG) has been demonstrated to alleviate spatial memory deficits in APP/PS1 transgenic mice. However, the mechanism by which RTG reduces cognitive deficits in APP/PS1 mice remains unclear. In this study, we revealed that RTG could ameliorate learning and spatial memory deficits in APP/PS1 mice during novel object recognition and Morris water maze tests. Meanwhile, RTG increased NeuN neuronal fluorescence intensity, increased the expression of the synaptic proteins postsynaptic density protein 95 (PSD95) and synaptophysin (SYN), improved synaptic plasticity, increased insulin-degrading enzyme (IDE) expression, decreased beta-secretase 1 (BACE1) expression, reduced Aβ1-40 and Aβ1-42 levels, and increased pAKT (ser473) and pGSK-3β (ser9) expression. These results indicated that RTG alleviates learning and spatial memory deficits in APP/PS1 mice, with potential mechanisms involving a reduction in neuronal loss, attenuation of synaptic damage, a decrease in β-amyloid (Aβ) deposition, and activation of the AKT/GSK-3β pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, Qingdao University Medical College, China. Electronic address: zhangxinyao0810@163.com.
- Central Pharmacy, Qingdao Municipal Hospital, China. Electronic address: 13645326227@163.com.
- Department of Pharmacology, School of Pharmacy, Qingdao University Medical College, China. Electronic address: DongpeiZhuangQDU@163.com.
- Department of Pharmacology, School of Pharmacy, Qingdao University Medical College, China. Electronic address: mzya0412@163.com.
- Department of Pharmacology, School of Pharmacy, Qingdao University Medical College, China. Electronic address: jucx@qdu.edu.cn.
Förderung
- Ministry of Science and Technology of the People's Republic of China
- Shandong Province Natural Science Foundation
- Department of Science and Technology of Guangdong Province
- Project of Shandong Province Higher Educational Science and Technology Program
Zitieren
APA
Zhang, X., Yang, X., Zhuang, D., Mu, Z., & Ju, C. (2026). Retigabine alleviates cognitive deficits, decreases neuropathology and activates the AKT/GSK-3β pathway in APP/PS1 transgenic mice. Behavioural Brain Research, 514, 116391. https://doi.org/10.1016/j.bbr.2026.116391
Vancouver
Zhang X, Yang X, Zhuang D, Mu Z, Ju C. Retigabine alleviates cognitive deficits, decreases neuropathology and activates the AKT/GSK-3β pathway in APP/PS1 transgenic mice. Behavioural Brain Research. 2026;514:116391. doi:10.1016/j.bbr.2026.116391
BibTeX
@article{Zhang2026,
author = {Zhang, Xinyao and Yang, Xu and Zhuang, Dongpei and Mu, Zhiyi and Ju, Chuanxia},
title = {Retigabine alleviates cognitive deficits, decreases neuropathology and activates the AKT/GSK-3β pathway in APP/PS1 transgenic mice},
journal = {Behavioural Brain Research},
year = {2026},
volume = {514},
pages = {116391},
doi = {10.1016/j.bbr.2026.116391}
}
EUVIMED